Antidiabetic treatment restores adiponectin serum levels and APPL1 expression, but does not improve adiponectin-induced vasodilation and endothelial dysfunction in Zucker diabetic fatty rats

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Schmid, Peter M ^a   Resch, Markus ^a   Schach, Christian ^a   Birner, Christoph ^a   Riegger, Guenter A ^a   Luchner, Andreas ^a   Endemann, Dierk H ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Adiponectin; AdipoR; APPL1; Diabetes mellitus type 2; eNOS; Insulin; Metformin

Indexed keywords

ADAPTOR PROTEIN; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; APPL1 PROTEIN; GLUCOSE; INSULIN; METFORMIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY RESISTANCE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HEART RATE; MALE; MESENTERIC ARTERY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASODILATATION; WEIGHT GAIN; ZUCKER DIABETIC FATTY RAT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADIPONECTIN; ANIMALS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; MALE; MESENTERIC ARTERIES; NERVE TISSUE PROTEINS; RATS; RATS, ZUCKER; TREATMENT OUTCOME; VASODILATION;

EID: 84875016899     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-46     Document Type: Article

References (56)

1. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270(45):26746-26749. 10.1074/jbc.270.45.26746, 7592907.
2. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996, 271(18):10697-10703. 10.1074/jbc.271.18.10697, 8631877.
3. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221(2):286-289. 10.1006/bbrc.1996.0587, 8619847.
4. Yatagai T, Nagasaka S, Taniguchi A, Fukushima M, Nakamura T, Kuroe A, Nakai Y, Ishibashi S. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 2003, 52(10):1274-1278. 10.1016/S0026-0495(03)00195-1, 14564678.
5. Basu R, Pajvani UB, Rizza RA, Scherer PE. Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes 2007, 56(8):2174-2177. 10.2337/db07-0185, 17513700.
6. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257(1):79-83. 10.1006/bbrc.1999.0255, 10092513.
7. Hajer GR, Van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008, 29(24):2959-2971. 10.1093/eurheartj/ehn387, 18775919.
8. Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005, 257(2):167-175. 10.1111/j.1365-2796.2004.01426.x, 15656875.
9. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005, 6(1):13-21. 10.1111/j.1467-789X.2005.00159.x, 15655035.
10. Gil-Campos M, Canete RR, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004, 23(5):963-974. 10.1016/j.clnu.2004.04.010, 15380884.
11. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 2008, 114(5):361-374.
12. Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007, 49(5):531-538. 10.1016/j.jacc.2006.08.061, 17276175.
13. Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res 2007, 74(1):11-18. 10.1016/j.cardiores.2006.10.009, 1858678, 17140553.
14. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423(6941):762-769. 10.1038/nature01705, 12802337.
15. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007, 13(3):332-339. 10.1038/nm1557, 17268472.
16. Heiker JT, Kosel D, Beck-Sickinger AG. Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors. Biol Chem 2010, 391(9):1005-1018.
17. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, Fang Q, Christ-Roberts CY, Hong JY, Kim RY. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 2006, 8(5):516-523. 10.1038/ncb1404, 16622416.
18. Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab 2009, 296(1):E22-E36. 2636986, 18854421.
19. Buechler C, Wanninger J, Neumeier M. Adiponectin receptor binding proteins-recent advances in elucidating adiponectin signalling pathways. FEBS Lett 2010, 584(20):4280-4286. 10.1016/j.febslet.2010.09.035, 20875820.
20. Hosch SE, Olefsky JM, Kim JJ. APPLied mechanics: uncovering how adiponectin modulates insulin action. Cell Metab 2006, 4(1):5-6. 10.1016/j.cmet.2006.06.003, 16814726.
21. Wang C, Xin X, Xiang R, Ramos FJ, Liu M, Lee HJ, Chen H, Mao X, Kikani CK, Liu F. Yin-Yang regulation of adiponectin signaling by APPL isoforms in muscle cells. J Biol Chem 2009, 284(46):31608-31615. 10.1074/jbc.M109.010355, 2797231, 19661063.
22. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003, 278(45):45021-45026. 10.1074/jbc.M307878200, 12944390.
23. Hattori Y, Suzuki M, Hattori S, Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 2003, 46(11):1543-1549. 10.1007/s00125-003-1224-3, 14551684.
24. Cheng KK, Lam KS, Wang Y, Huang Y, Carling D, Wu D, Wong C, Xu A. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes 2007, 56(5):1387-1394. 10.2337/db06-1580, 17287464.
25. Xi W, Satoh H, Kase H, Suzuki K, Hattori Y. Stimulated HSP90 binding to eNOS and activation of the PI3-Akt pathway contribute to globular adiponectin-induced NO production: vasorelaxation in response to globular adiponectin. Biochem Biophys Res Commun 2005, 332(1):200-205. 10.1016/j.bbrc.2005.04.111, 15896318.
26. Schmid PM, Resch M, Steege A, Fredersdorf-Hahn S, Stoelcker B, Birner C, Schach C, Buechler C, Riegger GA, Luchner A. Globular and full-length adiponectin induce NO-dependent vasodilation in resistance arteries of Zucker lean but not Zucker diabetic fatty rats. Am J Hypertens 2011, 24(3):270-277. 10.1038/ajh.2010.239, 21151013.
27. Cao Y, Tao L, Yuan Y, Jiao X, Lau WB, Wang Y, Christopher T, Lopez B, Chan L, Goldstein B. Endothelial dysfunction in adiponectin deficiency and its mechanisms involved. J Mol Cell Cardiol 2009, 46(3):413-419. 10.1016/j.yjmcc.2008.10.014, 2671019, 19027750.
28. Deng G, Long Y, Yu YR, Li MR. Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS Pathway. Int J Obes (Lond) 2010, 34(1):165-171.
29. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, Kumada M, Ohashi K, Okamoto Y, Nishizawa H. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003, 42(3):231-234. 10.1161/01.HYP.0000083488.67550.B8, 12860835.
30. Quaile MP, Melich DH, Jordan HL, Nold JB, Chism JP, Polli JW, Smith GA, Rhodes MC. Toxicity and toxicokinetics of metformin in rats. Toxicol Appl Pharmacol 2010, 243(3):340-347. 10.1016/j.taap.2009.11.026, 20004680.
31. Tian J, Wang J, Li Y, Villarreal D, Carhart R, Dong Y, Wen Y, Liu K. Endothelial function in patients with newly diagnosed type 2 diabetes receiving early intensive insulin therapy. Am J Hypertens 2012, 25(12):1242-1248.
32. Metais C, Forcheron F, Abdallah P, Basset A, Del Carmine P, Bricca G, Beylot M. Adiponectin receptors: expression in Zucker diabetic rats and effects of fenofibrate and metformin. Metabolism 2008, 57(7):946-953. 10.1016/j.metabol.2008.02.010, 18555836.
33. Sena CM, Matafome P, Louro T, Nunes E, Fernandes R, Seica RM. Metformin restores endothelial function in aorta of diabetic rats. Br J Pharmacol 2011, 163(2):424-437. 10.1111/j.1476-5381.2011.01230.x, 3087142, 21250975.
34. Sartoretto JL, Melo GA, Carvalho MH, Nigro D, Passaglia RT, Scavone C, Cuman RK, Fortes ZB. Metformin treatment restores the altered microvascular reactivity in neonatal streptozotocin-induced diabetic rats increasing NOS activity, but not NOS expression. Life Sci 2005, 77(21):2676-2689. 10.1016/j.lfs.2005.05.022, 15964597.
35. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002, 290(3):1084-1089. 10.1006/bbrc.2001.6307, 11798186.
36. Pereira RI, Draznin B. Inhibition of the phosphatidylinositol 3'-kinase signaling pathway leads to decreased insulin-stimulated adiponectin secretion from 3T3-L1 adipocytes. Metabolism 2005, 54(12):1636-1643. 10.1016/j.metabol.2005.07.002, 16311098.
37. Blumer RM, Van Roomen CP, Meijer AJ, Houben-Weerts JH, Sauerwein HP, Dubbelhuis PF. Regulation of adiponectin secretion by insulin and amino acids in 3T3-L1 adipocytes. Metabolism 2008, 57(12):1655-1662. 10.1016/j.metabol.2008.07.020, 19013287.
38. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116(7):1784-1792. 10.1172/JCI29126, 1483172, 16823476.
39. Mohlig M, Wegewitz U, Osterhoff M, Isken F, Ristow M, Pfeiffer AF, Spranger J. Insulin decreases human adiponectin plasma levels. Horm Metab Res 2002, 34(11-12):655-658.
40. Fujita H, Fujishima H, Koshimura J, Hosoba M, Yoshioka N, Shimotomai T, Morii T, Narita T, Kakei M, Ito S. Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice. Endocr J 2005, 52(4):427-433. 10.1507/endocrj.52.427, 16127210.
41. Cui XB, Wang C, Li L, Fan D, Zhou Y, Wu D, Cui QH, Fu FY, Wu LL. Insulin decreases myocardial adiponectin receptor 1 expression via PI3K/Akt and FoxO1 pathway. Cardiovasc Res 2012, 93(1):69-78. 10.1093/cvr/cvr273, 22012952.
42. Zulian A, Cancello R, Girola A, Gilardini L, Alberti L, Croci M, Micheletto G, Danelli P, Invitti C. In vitro and in vivo effects of metformin on human adipose tissue adiponectin. Obes Facts 2011, 4(1):27-33. 10.1159/000324582, 21372608.
43. Hanefeld M, Pfutzner A, Forst T, Kleine I, Fuchs W. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study. Cardiovasc Diabetol 2011, 10:65. 10.1186/1475-2840-10-65, 3160877, 21756323.
44. Doogue MP, Begg EJ, Moore MP, Lunt H, Pemberton CJ, Zhang M. Metformin increases plasma ghrelin in Type 2 diabetes. Br J Clin Pharmacol 2009, 68(6):875-882. 10.1111/j.1365-2125.2009.03372.x, 2810798, 20002081.
45. Tarkun I, Dikmen E, Cetinarslan B, Canturk Z. Impact of treatment with metformin on adipokines in patients with polycystic ovary syndrome. Eur Cytokine Netw 2010, 21(4):272-277.
46. Sofer E, Boaz M, Matas Z, Mashavi M, Shargorodsky M. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism 2011, 60(9):1278-1284. 10.1016/j.metabol.2011.01.011, 21411114.
47. Gomez-Diaz RA, Talavera JO, Pool EC, Ortiz-Navarrete FV, Solorzano-Santos F, Mondragon-Gonzalez R, Valladares-Salgado A, Cruz M, Aguilar-Salinas CA, Wacher NH. Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial. Metabolism 2012, 61(9):1247-1255. 10.1016/j.metabol.2012.02.003, 22424822.
48. Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry RR. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003, 52(3):667-674. 10.2337/diabetes.52.3.667, 12606507.
49. Adamia N, Virsaladze D, Charkviani N, Skhirtladze M, Khutsishvili M. Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes. Georgian Med News 2007, 145:52-55.
50. Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Crandall J, Marcovina S, Goldstein B, Goldberg R. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008, 57(4):980-986. 10.2337/db07-1419, 2529455, 18192541.
51. Steiner CA, Janez A, Jensterle M, Reisinger K, Forst T, Pfutzner A. Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. J Diabetes Sci Technol 2007, 1(2):211-217. 2771474, 19888409.
52. Sattar AA, Sattar R. Insulin-regulated expression of adiponectin receptors in muscle and fat cells. Cell Biol Int 2012, 36(12):1293-1297. 10.1042/CBI20120294, 23043361.
53. Sun X, He J, Mao C, Han R, Wang Z, Liu Y, Chen Y. Negative regulation of adiponectin receptor 1 promoter by insulin via a repressive nuclear inhibitory protein element. FEBS Lett 2008, 582(23-24):3401-3407.
54. Zanetti M, Barazzoni R, Stebel M, Roder E, Biolo G, Baralle FE, Cattin L, Guarnieri G. Dysregulation of the endothelial nitric oxide synthase-soluble guanylate cyclase pathway is normalized by insulin in the aorta of diabetic rat. Atherosclerosis 2005, 181(1):69-73. 10.1016/j.atherosclerosis.2005.01.011, 15939056.
55. Murthy SN, Pankey EA, Banka AA, Badejo AM, Wekerle R, Vilija V, Izadpanah R, Kadowitz PJ, Fonseca VA. Effects of insulin detemir on balloon catheter injured carotid artery in Zucker fatty rats. J Diabetes Complications 2012, 26(6):470-475. 10.1016/j.jdiacomp.2012.05.019, 22770941.
56. Matsumoto T, Noguchi E, Ishida K, Kobayashi T, Yamada N, Kamata K. Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes. Am J Physiol Heart Circ Physiol 2008, 295(3):H1165-H1176. 10.1152/ajpheart.00486.2008, 18641273.